Technology

Cura Therapeutics is developing a first-in-class multifunctional immunotherapy platform to treat a wide range of solid malignancies, infectious diseases, and other undisclosed applications. Cura's immunotherapies harness cytokines and immune receptors to create multifunctional proteins with novel immunomodulatory properties.

Technological Innovation: Cura's lead immunotherapy CT101 is a multifunctional cytokine fusion protein that activates and synchronizes major immune system mechanisms to destroy cancer cells.

1. Induces robust immune effector cell activation and migration in the tumor site.
2. Reduces the immunosuppressive tumor microenvironment.
3. Disrupts the tumor's blood supply, which prevents tumor growth and spread.

Competitive Advantage: Cura Therapeutics competitive advantage is our immunotherapies multifunctional approach. Our lead immunotherapy, CT101, is the first-in-class biological drug that contemporaneously engages immunostimulatory, anti-metastatic, and anti-angiogenesis activities against solid malignancies. Currently, no treatments on the market combine these major anti-cancer properties in one drug.

Our lead immunotherapy, CT101, constitutes a new approach to treating patients with metastatic cancer. CT101 has the potential to substantially increase the survival rate and quality of life in patients with metastatic cancer over the current standard of care.

Partnering &
Collaborations

Cura Therapeutics is actively seeking strategic partnering opportunities, and collaborations with pharmaceutical and biotechnology companies to develop and commercialize cancer immunotherapies based on our multifunctional fusion proteins.